Ociperlimab

国际站：Ociperlimab

CAS：2342597-93-5

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Ociperlimab 是一种人源化 IgG1 抗 TIGIT 抗体。Ociperlimab 以高亲和力结合人 TIGIT 的细胞外结构域 (KD = 0.135 nM)。Ociperlimab 阻断 TIGIT 与其配体 PVR 或 PVR-L2 之间的相互作用。Ociperlimab 可用于癌症研究。

体外：Ociperlimab (BGB-A1217; 0-10 μg/mL) 增强增强巨细胞病毒特异性 T 细胞分泌的 IFN-γ[1]。 Ociperlimab (1-1000 ng/mL) 以 Fc 依赖性方式激活自然杀伤细胞和单核细胞[1]。 Ociperlimab 在体外通过 Fc 依赖性内吞作用从 T 细胞表面去除 TIGIT[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内：Ociperlimab (BGB-A1217; 3 和 10 mg/kg; 腹腔注射; CT26 WT 荷瘤人源化 TIGIT 敲入小鼠和 MC38 荷瘤人源化 TIGIT 敲入小鼠) 以 Fc 依赖性方式产生抗肿瘤功效[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: CT26 WT tumor-bearing humanized TIGIT knock-in mice and MC38 tumor-bearing humanized TIGIT knock-in mice[1] Dosage: 3 and 10 mg/kg Administration: Intraperitoneal injection Result: Inhibited tumor growth compared to the single agent treatment groups. Clinical Trial

参考文献：[1]. Chen X, et, al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. Front Immunol. 2022 Feb 22;13:828319.[2]. Zhu J, et, al. Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation. Mol Biol Rep. 2022 Dec 26.